The YouTuber sees Insulet as a good entry opportunity despite recent pressure from weight-loss drugs, arguing the sell-off is overdone. They believe the company, as a market leader in insulin pump systems, offers a good long-term risk-reward profile, especially given its strong growth in the Omnipod system and potential for international expansion. The current P/E of 37 is considered fair for a market leader with growth potential, even if analysts' growth estimates are conservative.
“ich persönlich halte den Abverkauf nämlich für übertrieben und sehe hier eine gute Einstiegsmöglichkeit da das Unternehmen ein führendes Medizintechnikunternehmen in einer sehr interessanten Nische ist” — ▶ 2:00